How should metastatic prostate cancer with a low prostate-specific antigen (PSA) be managed?

Management of Metastatic Prostate Cancer with Low PSA

For metastatic prostate cancer with low PSA, you should initiate androgen deprivation therapy (ADT) combined with a second-generation androgen receptor pathway inhibitor (abiraterone, enzalutamide, or apalutamide) regardless of PSA level, as these combinations improve overall survival and progression-free survival in all metastatic castration-sensitive disease. 1, 2

Initial Treatment Algorithm

First-Line Systemic Therapy Options

All patients with metastatic castration-sensitive prostate cancer should receive ADT plus one of the following, with selection based on cost and patient-specific tolerability: 1, 2

• Apalutamide 240 mg daily plus ADT (Category 1 recommendation, proven survival benefit across all disease volumes including low-volume disease) 2
• Enzalutamide 160 mg daily plus ADT (strong recommendation with high-quality evidence for both de novo and recurrent metastatic disease) 1
• Abiraterone 1,000 mg daily with prednisone 5 mg daily plus ADT (strong recommendation for high-risk disease per LATITUDE; moderate recommendation for low-risk disease per STAMPEDE) 1

Disease Volume Stratification

The treatment approach does not change based on PSA level, but disease volume matters: 1

• High-volume disease (visceral metastases or ≥4 bone lesions with ≥1 beyond vertebral bodies/pelvis): All three androgen receptor pathway inhibitors have strong evidence 1, 2
• Low-volume disease: Abiraterone has moderate-strength evidence; apalutamide and enzalutamide have strong evidence across all volumes 1, 2

Critical Considerations for Low PSA Disease

Recognize Aggressive Histology

Low PSA metastatic prostate cancer frequently indicates poorly differentiated or neuroendocrine features: 3, 4

• Check alternative tumor markers: CEA, CA19-9, CA15-3, CA125, chromogranin A, and neuron-specific enolase, as these are often elevated when PSA is low 3, 4
• Review pathology for neuroendocrine differentiation: Small cell carcinoma or poorly differentiated adenocarcinoma is present in up to 87.5% of low-PSA metastatic cases 3
• Expect visceral metastases and lytic bone disease: These occur more frequently in low-PSA disease (liver 55.5%, lymph nodes 44.4%, lung 33.3%; lytic or mixed bone lesions in 33.3%) 3

Monitoring Strategy

Do not rely solely on PSA for disease monitoring in low-PSA metastatic prostate cancer: 3, 4

• Serial imaging (CT, bone scan, or PSMA-PET) is essential for assessing treatment response 3
• Monitor alternative tumor markers (CEA, chromogranin A, NSE) if elevated at baseline 3, 4
• PSA may remain low or undetectable despite disease progression 4, 5

Treatment Sequencing After Progression

If Disease Progresses on First-Line Androgen Receptor Pathway Inhibitor

Switch to docetaxel chemotherapy (75 mg/m² IV every 3 weeks for up to 6 cycles) as the preferred next option due to cross-resistance between androgen receptor pathway inhibitors: 2

• Continue ADT indefinitely throughout all subsequent lines of therapy 2
• Consider platinum-based chemotherapy if neuroendocrine features are present, as these tumors show sensitivity to cisplatin-based regimens (66.6% objective response rate) 3

Subsequent Options After Chemotherapy

• PSMA-targeted radioligand therapy (lutetium-177-PSMA-617) if PSMA-avid disease on imaging 6, 7
• PARP inhibitors (olaparib) if BRCA1/2 or homologous recombination repair mutations are present 6
• Radium-223 for symptomatic bone metastases without visceral involvement 6

Common Pitfalls to Avoid

• Never delay treatment waiting for PSA to rise—low PSA with radiographic metastases requires immediate systemic therapy 3, 8
• Never use first-generation antiandrogens (bicalutamide, flutamide) as they provide inferior survival compared to second-generation agents 2
• Never assume low PSA means indolent disease—it often indicates aggressive, poorly differentiated histology with worse prognosis 3, 4, 8
• Never switch between androgen receptor pathway inhibitors at progression—use docetaxel instead due to cross-resistance 2
• Never stop ADT even when adding other therapies or at progression 2

Bone Health and Supportive Care

Initiate bone-protective therapy for all patients on ADT: 2

• Zoledronic acid 4 mg IV annually or alendronate 70 mg PO weekly if fracture risk warrants treatment 2
• Calcium 1,200 mg daily and vitamin D3 800-1,000 IU daily for all men over 50 on ADT 2

Prognosis Considerations

Patients with initial PSA <200 ng/mL and extensive bone metastases (EOD score ≥2) have significantly shorter overall survival despite similar progression-free survival with androgen receptor signaling inhibitors, suggesting more aggressive biology: 8

• This population still benefits from first-line ARSI treatment 8
• Consider earlier transition to chemotherapy or clinical trial enrollment 8